financetom
Business
financetom
/
Business
/
Cognizant Technology Solutions' Soft Q2 Guidance Comes Amid Complex Macro Backdrop, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cognizant Technology Solutions' Soft Q2 Guidance Comes Amid Complex Macro Backdrop, Wedbush Says
Apr 30, 2026 11:11 AM

01:50 PM EDT, 04/30/2026 (MT Newswires) -- Cognizant Technology Solutions' ( CTSH ) relatively soft Q2 guidance comes amid a dynamic macroeconomic backdrop as clients remain careful about making major investments, Wedbush said in a Thursday research report.

Robust Q1 bookings indicate steady demand for the company's services, but it will take time to deliver on this backlog considering the longer durations of such major deals, analysts wrote.

The acquisition of AI-based IT managed services provider Astreya is a favorable move by the company to bolster its AI builder strategy and become a "stronger operations engine," according to the note.

Cost savings from Project Leap that involves workforce restructuring and investments in AI-enabled skills for streamlining operations will be reinvested into future growth opportunities, according to analysts.

The brokerage reiterated its neutral rating on the stock and cut its price target to $56 per share from $61.

Price: 52.50, Change: -2.20, Percent Change: -4.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Checkpoint Therapeutics Says FDA Accepted Revised Biologics License Application for Cosibelimab
Checkpoint Therapeutics Says FDA Accepted Revised Biologics License Application for Cosibelimab
Jul 25, 2024
11:51 AM EDT, 07/25/2024 (MT Newswires) -- Checkpoint Therapeutics ( CKPT ) said Thursday that the US Food and Drug Administration has accepted for review its resubmission of the biologics license application for cosibelimab, with a Prescription Drug User Fee Act target date of Dec. 28. Cosibelimab is a potential treatment of advanced cutaneous squamous cell carcinoma, a type of...
Group 1 Auto to Offer $500 Million of Senior Unsecured Notes Due 2030
Group 1 Auto to Offer $500 Million of Senior Unsecured Notes Due 2030
Jul 25, 2024
11:44 AM EDT, 07/25/2024 (MT Newswires) -- Group 1 Automotive ( GPI ) early Thursday disclosed plans for a $500 million private placement of senior unsecured notes due 2030, subject to market conditions. The automotive retail chain expects to use the net proceeds from the upcoming offering to repay prior borrowings made through its revolving credit facility in addition to...
Update: Bombardier Loses Nearly 4% as Its Q2 Adjusted Profit Rises 39%
Update: Bombardier Loses Nearly 4% as Its Q2 Adjusted Profit Rises 39%
Jul 25, 2024
11:46 AM EDT, 07/25/2024 (MT Newswires) -- Bombardier (BBD-B.TO) on Thursday said its second-quarter adjusted profit rose 39% as revenue rose by nearly a third, driven by higher aircraft deliveries and a steady increase in services revenue. The company said its second-quarter adjusted profit, excluding most one-time items. rose to US$111 million, or US$1.04 per share, up from US$0 million,...
Hasbro Lifts Full-Year Core Profitability Outlook as Quarterly Results Beat Estimates
Hasbro Lifts Full-Year Core Profitability Outlook as Quarterly Results Beat Estimates
Jul 25, 2024
11:46 AM EDT, 07/25/2024 (MT Newswires) -- Hasbro ( HAS ) on Thursday increased its full-year outlook for core profitability as second-quarter results came in ahead of market expectations, aided by margin improvement. Adjusted earnings per share advanced to $1.22 for the three months ended June 30 from $0.49 last year and surpassed the $0.76 average analyst estimate on Capital...
Copyright 2023-2026 - www.financetom.com All Rights Reserved